Related Experiment Video
Updated: Nov 20, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Novel developments in chronic myeloid leukaemia
Patrick Harrington1,2, Hugues de Lavallade1,2,3
1School of Cancer & Pharmaceutical Science, King's College London.
Insights
Recent advances in chronic myeloid leukemia (CML) include new biomarkers for treatment-free remission and strategies for managing tyrosine kinase inhibitor (TKI) resistance. This review covers key clinical and pathophysiological developments in CML management.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) remains a significant hematologic malignancy.
- Continuous research is vital for improving patient outcomes and understanding disease mechanisms.
Purpose of the Study:
- To review significant advancements in chronic myeloid leukemia (CML) over the past year.
- To highlight key developments in clinical management and disease pathophysiology.
- To provide context with relevant prior publications.
Main Methods:
- Conducted a PubMed search for relevant papers and abstracts from the last year.
- Included pertinent earlier publications for comprehensive context.
- Focused on clinical management, pathophysiology, and emerging therapeutic strategies.
Main Results:
- Discussed novel biomarkers for achieving treatment-free remission in CML patients.
- Reviewed outcomes from second-generation tyrosine kinase inhibitor (TKI) discontinuation studies.
- Examined new techniques for assessing TKI resistance and novel management approaches for resistant cases, including combination therapies.
Conclusions:
- The review summarizes critical research in CML, covering diagnostic techniques, biomarkers, and novel therapeutic options.
- Emerging strategies offer new hope for managing CML, particularly in cases of resistance.
- Continued investigation into CML pathophysiology and treatment is essential.
Purpose Of Review:
Despite unprecedented challenges during the preceding year, there have been a wide range of significant advances in the field of chronic myeloid leukaemia. In this review article we highlight papers reporting on some of the most important developments over the last year, both with regards to the clinical management of patients with chronic myeloid leukaemia, as well as studies that help to increase our understanding of the pathophysiology of the disease. We have performed a PubMed search to identify important papers and abstracts listed over the last year and have included additional papers published prior to this, where relevant, to provide context.
Recent Findings:
We comment on novel biomarkers for treatment free remission as well as recent results from second generation Tyrosine Kinase Inhibitor (TKI) discontinuation studies. We discuss new techniques that are being used to assess TKI resistance as well as reviewing novel and emerging approaches to the management of resistant patients, including the use of combination therapies.
Summary:
This review highlights some of the most important research to have been reported over the last year in the field of chronic myeloid leukaemia, encompassing emerging diagnostic techniques, biomarkers and novel therapeutic options.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...